ArticleCureus2026
Epstein-Barr Virus (EBV) Hepatitis Treated With N-Acetylcysteine: Placebo Versus True Effect.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) is a herpesvirus that is known to cause multiple conditions, ranging from malignancies like Hodgkin and non-Hodgkin lymphomas to infectious and autoimmune conditions like infectious mononucleosis and systemic lupus erythematosus. Infectious mononucleosis causes systemic symptoms including cervical lymphadenopathy, splenomegaly, malaise, myalgias, and fever. While the spleen and liver are involved in some cases, most cases result in mild elevation of transaminases, not exceeding two to three times the upper normal limit. The transaminitis is usually subclinical with a self-limiting course. On rare occasions, liver involvement is associated with significant transaminitis reaching up to 10 times the upper normal limit. These patients usually also present with jaundice. Such severe or fatal hepatitis is most commonly seen in immunocompromised individuals. Here, we present a 31-year-old man who came to us with progressive jaundice, upper quadrant abdominal pain, and greasy stools after what he thought was just the flu. The patient was found to have EBV-induced hepatitis, requiring N-acetylcysteine administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.